Abstract
In January 2009, tocilizumab (RoActemra; Chugai/Roche), a humanized monoclonal antibody that binds to the interleukin-6 receptor, was granted marketing authorization by the European Commission for the treatment of moderate to severe rheumatoid arthritis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Smolen, J. S. et al. New therapies for the treatment of rheumatoid arthritis. Lancet 370, 1861–1874 (2007).
Nishimoto, N. & Kishimoto, T. Interleukin 6: from bench to bedside. Nature Clin. Pract. Rheumatol. 2, 619–626 (2006).
Sack, U. et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol. Int. 13, 45–51 (1993).
Madhok, R. et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann. Rheum. Dis. 52, 232–234 (1993).
Alonzi, T. et al. Interleukin 6 is required for the development of collagen-induced arthritis. J. Exp. Med. 187, 461–468 (1998).
Takagi N. et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum. 41, 2117–2121 (1998).
Sato, K. et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res. 53, 851–856 (1993).
European Medicines Agency (EMEA). European Public Assessment Report – RoActemra. EMEA website [online] (2008).
Jones, G. et al. Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 67 (Suppl. II), 89 (2008).
Kremer, J. M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE Study. Arthritis Rheum. 58, 4031 (2008).
Smolen, J. S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987–997 (2008).
Genovese, M. C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968–2980 (2008).
Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516–1523 (2008).
Mierau, M. et al. Assessing remission in clinical practice. Rheumatology 46, 975–979 (2007).
Smolen, J. S. et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade. Ann. Rheum. Dis. 7 Jul 2008 (doi: 10.1136/ard.2008.090019).
IMS MIDAS (2009).
Therapeutic categories outlook: arthritis & inflammation (Cowen and Company, 2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J.S. has received honoraria and grant support from Roche, Centocor/Schering-Plough, Abbott, Amgen, Wyeth, Bristol-Myers Squibb and UCB.
Rights and permissions
About this article
Cite this article
Scheinecker, C., Smolen, J., Yasothan, U. et al. Tocilizumab. Nat Rev Drug Discov 8, 273–274 (2009). https://doi.org/10.1038/nrd2863
Issue Date:
DOI: https://doi.org/10.1038/nrd2863
This article is cited by
-
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells
Leukemia (2016)
-
BMS acquires rights for IL-6 inhibitor
Nature Reviews Drug Discovery (2010)
-
Biopharmaceutical benchmarks 2010
Nature Biotechnology (2010)